Articles from Olink Proteomics AB

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the UK Competition and Markets Authority (the “CMA”) has unconditionally approved the previously announced tender offer (the “Offer”) by Orion Acquisition AB (the “Buyer”), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSETMO) (“Thermo Fisher” or “Parent”), for all outstanding Common Shares and American Depositary Shares (together, the “Shares”) of Olink for $26.00 per Share.

UPPSALA, Sweden, July 05, 2024 (GLOBE NEWSWIRE) -- At the Extra General Meeting (the “EGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), the EGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the EGM and the complete proposals, which have previously been published and are available on the Company’s website, www.olink.com.

UPPSALA, Sweden, July 03, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK), a global leader in proteomics, introduces its inaugural network of Olink® Certified Service Providers. The group of Olink Certified Service Providers represent leading contract research organizations (CROs) and service labs around the world.

This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail.

UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.

UPPSALA, Sweden, May 30, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers.

UPPSALA, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2024.

UPPSALA, Sweden, April 19, 2024 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 19 April 2024 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.olink.com.

UPPSALA, Sweden, April 02, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of an open access data library consisting of over 300,000 protein-disease risk associations, giving researchers a powerful new tool for revealing the biological mechanisms underlying 106 human diseases.

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2023 is now available on the Company’s website at https://investors.olink.com/.

UPPSALA, Sweden, March 25, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter ended December 31, 2023.

UPPSALA, Sweden, March 15, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Friday the 19 April 2024, in the Company’s facilities at Salagatan 16A, Uppsala. Registration for the meeting commences at 3:30 p.m. CET.

UPPSALA, Sweden, March 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Olink’s 2024 Annual General Meeting (“AGM”) will be held in Uppsala, Sweden on April 19th, 2024. The AGM was previously scheduled to take place on April 17th, 2024.

UPPSALA, Sweden, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter ended September 30, 2023.

UPPSALA, Sweden, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that Novogene Asia Pacific Middle East and Africa (AMEA) has adopted the Olink Explore HT platform to deliver advanced next-generation proteomics technology to the scientific community in the region.

UPPSALA, Sweden, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale.

Discover more with less. Unmatched specificity and sensitivity deliver translational insights from 1µl of sample.

Uppsala, Sweden, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Eurofins Genomics adopts Olink® technology to advance proteomics research and accelerate precision medicine programs

UPPSALA, Sweden, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:

UPPSALA, Sweden, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the second quarter ended June 30, 2023.

UPPSALA, Sweden, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Baylor College of Medicine Human Genome Sequencing Center (BCM-HGSC) has selected the Olink Explore platform as a proteomics component of their world-class multiomics offering.

UPPSALA, Sweden, July 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the second quarter of 2023 before the market open on Wednesday, August 9, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.

A High-throughput Protein Biomarker Discovery Platform with Proven Specificity at Any Scale

UPPSALA, Sweden, June 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the availability of new findings into the variability of the human proteome, based on measurements of approximately 1,500 proteins in over 50,000 participants from the UK Biobank (UKB). The findings will be shared through the Normal Ranges tool on Olink Insight, providing researchers with an unprecedented view into the biological variations in protein levels, measured for the first time at population scale. This unique dataset represents a dramatic expansion of the information presented in Olink Insight and promises to significantly advance scientific understanding of the human proteome.

UPPSALA, Sweden, May 25, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:

UPPSALA, Sweden, May 11, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the first quarter ended March 31, 2023.

UPPSALA, Sweden, April 17, 2023 (GLOBE NEWSWIRE) -- At the Annual General Meeting (the “AGM”) of Olink Holding AB (publ), reg. no 559189-7755, (the “Company”), on 17 April 2023 the AGM adopted, inter alia, the following resolutions. For more detailed information regarding the contents of the resolutions, please refer to the notice to the AGM and the complete proposals, which have previously been published and are available on the Company’s website, www.olink.com.

UPPSALA, Sweden, April 13, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the first quarter of 2023 before the market open on Thursday, May 11, 2023. Company management will host a conference call to discuss these results at 8:00 am ET.

UPPSALA, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic facility, D-CYPHR in Cape Town, South Africa has adopted Olink technology and has become the first service provider using the Olink® Target and Olink® Flex platforms for targeted protein biomarker discovery on the African continent.

UPPSALA, Sweden, March 27, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced that the Annual Report for 2022 is now available on the Company’s website at https://investors.olink.com/.

UPPSALA, Sweden, March 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the appointment of life sciences industry veteran Bruno Rossi to the role of Chief Commercial Officer (CCO), effective immediately. Mr. Rossi will lead the Company’s global commercial organization including Sales, Marketing and Sales Operations. He will report to Carl Raimond, President of Olink.

UPPSALA, Sweden, March 15, 2023 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the “Company” or “Olink”), reg. no. 559189-7755, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CET on Monday the 17 April 2023, in the Company’s facilities at Salagatan 18B, Uppsala. Registration for the meeting commences at 3:30 p.m. CET.

UPPSALA, Sweden, March 06, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has launched the NUS Medicine Protein Biomarker Discovery Core Facility, which will provide the Olink® Explore 3072, Olink® Explore 1536, Olink® Target 96 and Target 48, and the recently launched Olink® Flex platforms. These solutions for advanced protein biomarker research range from high-plex, high throughput discovery to more targeted biomarker studies. The launch of this core facility at NUS Medicine strengthens Olink’s presence in the South Asia Pacific region, offering its highly innovative proteomics technologies to a wider audience.

UPPSALA, Sweden, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced an agreement with Regeneron Genetics Center® (RGC) focused on the use and development of Olink High-Plex offerings as a proteomics platform of choice, with a goal of generating proteomic data at scale to augment RGC’s vast genomics information store. RGC is a wholly owned subsidiary of Regeneron Pharmaceuticals, Inc. that focuses on early gene discovery and functional genomics to ultimately improve patient outcomes.

UPPSALA, Sweden, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2022.

Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the pricing of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ADSs”), consisting of 4,250,000 ADSs offered by the Company and 1,581,028 ADSs offered by certain selling shareholders of the Company (the “Selling Shareholders”), at a price to the public of $20.00 per ADS. In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 874,654 ADSs from the Company. The Company will not receive any proceeds from the sale of the ADSs by the Selling Shareholders. The offering is expected to close on or about January 23, 2023, subject to the satisfaction of customary closing conditions.

Uppsala, Sweden, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) (“Olink” or the “Company”), today announced the launch of a public offering of 5,831,028 American Depositary Shares, each representing one common share of the Company (the “ADSs”), consisting of 4,250,000 ADSs offered by the Company and 1,581,028 ADSs offered by certain selling shareholders of the Company (the “Selling Shareholders”). In addition, the Company is expected to grant the underwriters a 30-day option to purchase up to 874,654 additional ADSs. The Company will not receive any proceeds from the sale of the ADSs by the Selling Shareholders. The offering is subject to market and other conditions, and there can be no assurance as to whether, or when, the offering may be completed or as to the actual size or terms of the offering.

UPPSALA, Sweden, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink” or the “Company”) (Nasdaq: OLK), today announced preliminary unaudited revenue for the fourth quarter and year ended December 31, 2022, and additional selected unaudited performance metrics.

UPPSALA, Sweden, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced its participation in the 41st Annual JP Morgan Healthcare Conference.

UPPSALA, Sweden, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) is proud to announce the 2022 winner of the young researchers’ award, Novelties in Biomarkers, Maria Martin-Grau at the University of Valencia, Spain at the Biomarkers of the Future conference in Paris, France.

UPPSALA, Sweden, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that it is now taking orders for Olink® Flex, a fully flexible made-to-order product to select and combine up to 21 human proteins using absolute quantification in one biomarker panel.

UPPSALA, Sweden, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced its unaudited financial results for the third quarter of 2022.

UPPSALA, Sweden, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced the achievement of more than one thousand peer-reviewed publications citing the use of Olink® Proximity Extension Assay (PEA) technology, underscoring the widespread adoption and successful application of its protein biomarker solutions by the scientific community.

UPPSALA, Sweden, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced that Company management will participate in the following investor events:

UPPSALA, Sweden, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the launch of Olink® Insight, providing customers with an open-access online platform to share knowledge, with multiple tools to simplify users’ data experiences, and to provide more timely insights from their protein studies.

UPPSALA, Sweden, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK) today announced it will release financial results for the third quarter of 2022 before the market open on Thursday, November 10, 2022. Company management will host a conference call to discuss these results at 8:00 am ET.